Targeting H3K36 methyltransferases NSDs:a promising strategy for tumor targeted therapy  

作　　者：Xuerun Peng Qian Peng Lei Zhong 

机构地区：[1]Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China [2]Radiation Oncology Key Laboratory of Sichuan Province,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第7期1933-1934,共2页信号转导与靶向治疗（英文）

基　　金：This work was supported by the National Natural Science Foundation of China(81702286);the Research Fund of Science&Technology Department of Sichuan Province(2021YJ0134,2018JY0652);the Open Project of Radiation Oncology Key Laboratory of Sichuan Province(2020FSZLX04).

摘　　要：Recently,two studies published in Nature identified genetic changes in the nuclear receptor-binding SET domain protein(NSD)family of histone methyltransferases as oncogenic drivers in some malignancies,and revealed the nucleosome-based recognition and histone-modification mechanisms of NSD2 and NSD3.

关 键 词：METHYLTRANSFERASE TARGETED THERAPY 

分 类 号：R730.5[医药卫生—肿瘤]